Comparative Pharmacology
Head-to-head clinical analysis: EVZIO versus NALOXONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EVZIO versus NALOXONE.
EVZIO vs NALOXONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Naloxone is an opioid antagonist that competitively binds to mu-opioid receptors, reversing opioid-induced respiratory depression and analgesia.
Competitive antagonist at mu, kappa, and delta opioid receptors, reversing opioid effects.
2 mg intramuscular (IM) or subcutaneous (SC) autoinjector into anterolateral thigh; repeat every 2-3 minutes as needed for opioid overdose.
0.4-2 mg IV/IM/SC, may repeat every 2-3 minutes; if no response after 10 mg, reconsider diagnosis.
None Documented
None Documented
The terminal elimination half-life of naloxone in adults is approximately 1-2 hours. In neonates, half-life may be prolonged to 3-4 hours. Clinical context: Short half-life necessitates repeated dosing or continuous infusion for sustained opioid reversal, especially with long-acting opioids.
Clinical Note
moderateNaloxone + Teriflunomide
"The metabolism of Teriflunomide can be decreased when combined with Naloxone."
Clinical Note
moderateNaloxone + Sulfisoxazole
"The metabolism of Sulfisoxazole can be decreased when combined with Naloxone."
Clinical Note
moderateNaloxone + Erythromycin
"The metabolism of Erythromycin can be decreased when combined with Naloxone."
Clinical Note
moderateNaloxone + Cyclosporine
60-90 minutes in adults; shorter in neonates (3 hours); prolonged in hepatic impairment (up to 2-3 hours).
Naloxone undergoes extensive hepatic metabolism primarily via glucuronidation, with approximately 70% excreted in urine as naloxone-3-glucuronide. About 25% is excreted in feces via biliary elimination. Less than 1% is excreted unchanged in urine.
Renal: ~70% as metabolites (naloxone-3-glucuronide, naloxone-3-sulfate) and <2% unchanged; biliary/fecal: ~25% primarily as conjugated metabolites.
Category C
Category A/B
Opioid Antagonist
Opioid Antagonist
"The metabolism of Cyclosporine can be decreased when combined with Naloxone."